Skip to main content
WoMWeb of Medicine
SearchGraphHistory
Oncology›Condition·Updated Apr 17, 2026·v1

Colorectal Cancer

Colorectal cancer is a major global health burden with a rising incidence in younger populations. Diagnosis relies on colonoscopy and staging via CT/MRI. Management is increasingly personalized, utilizing Complete Mesocolic Excision (CME) or Total Mesorectal Excision (TME) for localized disease, and molecularly-targeted systemic therapies (anti-VEGF, anti-EGFR, or immunotherapy) for advanced stages. Universal MSI/MMR testing is mandatory for all new cases.

High Evidence265 references·11,048 words·45 min read·v1
Colorectal CancerOncologyGastroenterologyLynch SyndromeImmunotherapy

Quick Reference

RxDrug of choicemFOLFOX6 (Adjuvant Stage III); Pembrolizumab (First-line MSI-H metastatic)
AltAlternativesCAPOX (Capecitabine + Oxaliplatin); FOLFIRI + Bevacizumab (Metastatic)
⊘AvoidAnti-EGFR therapy (Cetuximab) in RAS-mutated or BRAF-mutated tumors
DxTest of choiceColonoscopy (Diagnosis); Pelvic MRI (Rectal staging)
ScKey scoreAJCC TNM Staging (8th/9th Edition); MSI/MMR status
→When to referDiagnosis of T1 cancer with high-risk features; suspected Lynch/FAP; metastatic disease for multidisciplinary review
Colorectal cancer management requires early screening starting at age 45, universal molecular profiling, and a combination of oncologically precise surgery and risk-adapted systemic therapy.
Colorectal cancer (CRC) is a malignant neoplastic disease arising from the epithelial lining of the colon or rectum, representing the third most common malignancy and the second leading cause of cancer-related mortality worldwide. While historically a disease of older adults, there is a significant global rise in early-onset colorectal cancer (EOCRC) in patients under age 50, often associated with obesity and distinct molecular profiles. Management has shifted from a one-size-fits-all surgical approach to a precision-medicine paradigm. Treatment is now dictated by anatomical location (right-sided vs. left-sided), TNM staging, and molecular markers including microsatellite instability (MSI) status, RAS, and BRAF mutations. Early detection through screening remains the most effective intervention, as localized disease carries a high cure rate, whereas metastatic disease requires complex, multi-agent systemic therapy and multidisciplinary coordination.

Overview and Recommendations

Background

  • •Recognize colorectal cancer (CRC) as a heterogeneous malignancy primarily manifesting as adenocarcinoma, originating from the glandular epithelium of the large intestine. It typically follows the adenoma-carcinoma sequence, driven by the accumulation of genetic mutations in the Wnt/β-catenin signaling pathway, or the serrated pathway characterized by BRAF mutations and CpG island methylator phenotype (CIMP).
  • •Identify the three primary molecular pathways: Chromosomal Instability (CIN), which accounts for 85% of sporadic cases; Microsatellite Instability (MSI), resulting from deficient mismatch repair (dMMR) seen in or sporadic MLH1 silencing; and the CIMP pathway. These pathways dictate tumor behavior, prognosis, and sensitivity to modern immunotherapies.
  • •Distinguish between anatomical subtypes, as right-sided (proximal) tumors often present with different molecular profiles and worse prognoses compared to left-sided (distal) tumors. Rectal cancer, defined as occurring within 15 cm of the anal verge, requires distinct management strategies due to the narrow pelvic anatomy and the necessity of preserving sphincter function.
  • •Screen for high-risk populations, including those with (Ulcerative Colitis or Crohn’s), hereditary syndromes like (FAP), or a significant family history. Emerging risk factors include central obesity, maternal obesity (intergenerational risk), and specific microbial signatures such as Fusobacterium nucleatum and Clostridioides difficile.
  • •Monitor the shifting epidemiology toward early-onset colorectal cancer (EOCRC). Patients diagnosed before age 50 often present with more advanced stages and distal lesions, necessitating a lower threshold for diagnostic workup in symptomatic young adults who might otherwise be misdiagnosed with benign conditions like .

Evaluation

  • •Suspect colorectal cancer in any adult presenting with iron-deficiency anemia, unexplained weight loss, or persistent changes in bowel habits such as new-onset constipation or 'pencil-thin' stools. Right-sided lesions often present with occult bleeding and fatigue, while left-sided lesions are more likely to cause overt and obstructive symptoms.
  • •Ask specifically about the duration of symptoms, as the clinical nadir typically occurs 2 to 4 months before presentation. Inquire about a family history of colorectal or endometrial cancers to screen for using the Amsterdam II or Bethesda criteria.
  • •Examine the patient thoroughly, starting with a mandatory digital rectal examination (DRE) to assess for low-lying rectal masses, fixation to surrounding tissues, and sphincter tone. Perform abdominal palpation to check for masses, hepatomegaly (suggestive of liver metastases), or (suggestive of peritoneal carcinomatosis).
  • •Order a high-quality as the gold standard for diagnosis. Utilize computer-aided detection (CADe) systems where available to maximize the adenoma detection rate (ADR). If colonoscopy is incomplete or contraindicated, consider Computed Tomographic Colonography (CTC) or colon capsule endoscopy.
  • •Obtain a tissue biopsy for histopathological confirmation and universal molecular testing. Every new diagnosis must be tested for mismatch repair (MMR) proteins (MLH1, MSH2, MSH6, PMS2) via immunohistochemistry or for microsatellite instability (MSI) via PCR to guide immunotherapy and identify hereditary risks.
  • •Perform systemic staging using contrast-enhanced CT of the chest, abdomen, and pelvis to identify distant metastases. For rectal cancer, obtain a high-resolution pelvic MRI to assess the circumferential resection margin (CRM), extramural venous invasion (EMVI), and the depth of invasion relative to the mesorectal fascia.
  • •Measure baseline serum Carcinoembryonic Antigen (CEA) levels. While not useful for screening due to low sensitivity, an elevated baseline CEA is a prognostic marker and serves as a vital tool for monitoring recurrence following curative-intent treatment.
  • •Evaluate nutritional and inflammatory status using indices like the Prognostic Nutritional Index (PNI) or the Systemic Immune-inflammation Index (SII). Low albumin and high neutrophil-to-lymphocyte ratios are independent predictors of poor surgical outcomes and reduced overall survival.
  • •Rule out paraneoplastic syndromes in atypical cases. For example, Erythema gyratum repens (a 'wood-grain' skin rash) or the sudden appearance of multiple seborrheic keratoses (Leser-Trélat sign) may be the first clinical indication of an underlying colonic malignancy.
  • •Consider genetic counseling and germline multigene panel testing (MGPT) for all patients diagnosed under age 50 or those with tumor testing suggestive of a hereditary syndrome, regardless of family history.

Management

  • •Initiate a multimodal prehabilitation program 2–4 weeks prior to elective surgery. This should include structured aerobic and resistance exercise, nutritional optimization, and psychological support to improve physiological reserve and reduce postoperative complications.
  • •Perform surgical resection as the primary curative modality for localized disease. For colon cancer, execute a (CME) with central vascular ligation. For rectal cancer, (TME) is the gold standard to ensure the removal of the intact mesorectal envelope.
  • •Utilize minimally invasive platforms, such as robotic-assisted surgery, particularly for complex rectal dissections. Robotic surgery is associated with lower conversion rates to open surgery and better visualization in the narrow male pelvis compared to conventional laparoscopy.
  • •Administer adjuvant chemotherapy for Stage III colon cancer to eradicate micrometastases. The standard regimen is mFOLFOX6 (Oxaliplatin 85 mg/m², Leucovorin 400 mg/m², and 5-FU 2400 mg/m² infusion) for 3 to 6 months depending on risk stratification (IDEA trial criteria).
  • •Optimize the timing of adjuvant therapy, especially in patients with lymph-vascular invasion (LVI). Initiating chemotherapy within 3.2 weeks of surgical resection is associated with significantly improved overall survival.
  • •Implement Total Neoadjuvant Therapy (TNT) for locally advanced rectal cancer. This involves delivering both chemotherapy (e.g., FOLFOX) and chemoradiotherapy (50.4 Gy with concurrent capecitabine) prior to surgery to increase pathological complete response (pCR) rates and facilitate organ preservation.
  • •Prescribe Pembrolizumab 200 mg IV every 3 weeks as the first-line standard of care for patients with microsatellite instability-high (MSI-H) or dMMR metastatic colorectal cancer, as established by the KEYNOTE-177 trial.
  • •Select targeted agents for metastatic disease based on RAS and BRAF status. For RAS wild-type, left-sided tumors, use anti-EGFR therapy (Cetuximab or Panitumumab). For RAS-mutated or right-sided tumors, combine chemotherapy with anti-VEGF therapy (Bevacizumab 5 mg/kg).
  • •Treat BRAF V600E-mutated metastatic disease with the combination of Encorafenib 300 mg daily plus Cetuximab, which has shown superior survival outcomes in the second-line setting compared to standard chemotherapy.
  • •Monitor for treatment-related toxicities, such as oxaliplatin-induced . Consider duloxetine 30–60 mg daily for established neuropathy or non-invasive magnetic field therapy for persistent pain.
  • •Manage high-output stomas (HOS) aggressively in the early postoperative period to prevent dehydration and electrolyte imbalances. Monitor stoma output daily; outputs exceeding 1500 mL/day require medical intervention with antimotility agents and oral rehydration solutions.
  • •Refer patients with colorectal peritoneal metastases for evaluation of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) with Mitomycin C 30 mg/m² at specialized centers.
  • •Follow a rigorous surveillance protocol post-resection: CEA testing every 3–6 months, annual CT scans of the chest/abdomen/pelvis, and colonoscopy at 1 year, then every 3–5 years based on findings.
  • •Incorporate liquid biopsy (ctDNA) monitoring where available to detect molecular residual disease (MRD). Post-surgical ctDNA positivity is a highly specific predictor of recurrence and may guide the intensification of adjuvant therapy.
  • •Avoid routine follow-up colonoscopy immediately after uncomplicated unless 'alarm' symptoms (anemia, weight loss) are present or the patient is over age 50 and overdue for screening.
  • •Refer all patients with suspected hereditary syndromes to a specialized genetics clinic for cascade testing of biological relatives to prevent future cancers in the family.

Board Review — High Yield

  • •Apple core lesion — Classic radiographic appearance of a constricting colorectal carcinoma on barium enema.
  • •Streptococcus gallolyticus (bovis) — Bacteremia or endocarditis with this organism is highly associated with underlying colorectal neoplasia; mandatory colonoscopy required.
  • •Lynch Syndrome — Autosomal dominant germline mutation in MMR genes (MLH1, MSH2, MSH6, PMS2); associated with proximal colon cancer and endometrial cancer.
  • •FAP (Familial Adenomatous Polyposis) — APC gene mutation on chromosome 5q; results in thousands of polyps and 100% cancer risk by age 40 if untreated.
  • •CEA (Carcinoembryonic Antigen) — Tumor marker used for monitoring recurrence, not for screening; high preoperative levels correlate with poor prognosis.
  • •Turcot Syndrome — Association of hereditary polyposis with CNS tumors (medulloblastoma or glioblastoma).
  • •Gardner Syndrome — FAP variant with extra-colonic manifestations including osteomas, desmoid tumors, and sebaceous cysts.
  • •Microsatellite Instability (MSI-H) — Predicts excellent response to PD-1 inhibitors (Pembrolizumab) but poor response to 5-FU monotherapy in Stage II.

Deep Dive — Evidence Details

References

  1. [1]

    Xu YB, Huang YS, Huang XX et al.. “Prognostic value of the prognostic nutritional index in colorectal cancer: a systematic review and meta-analysis.” BMC gastroenterology (2026). PMID: 41731387 ↗

    L2aSR_OBSCited in: Definition, Synonyms, and Classification
  2. [2]

    Wang P, Jiang H. “Prognostic value of systemic immune-inflammation index for colorectal cancer: a systematic review and meta-analysis.” Frontiers in oncology (2026). PMID: 41727644 ↗

    L2aSR_OBSCited in: Definition, Synonyms, and Classification
  3. [3]

    Wang Z, Zou J, Li Y et al.. “Prognostic and clinicopathological significance of heat shock proteins in colorectal cancer patients: a meta-analysis.” World journal of surgical oncology (2026). PMID: 41792786 ↗

    L2aSR_OBSCited in: Definition, Synonyms, and Classification
  4. [4]

    Manz NB, Reed J, Kanner CD et al.. “Temporal change in skeletal muscle index as a predictor of recurrence for patients with locally advanced colorectal malignancy: a retrospective cohort study.” Cancer imaging : the official publication of the International Cancer Imaging Society (2026). PMID: 41947259 ↗

    L2bCOHORTCited in: Definition, Synonyms, and Classification, Prognosis and Long-term Outcomes
  5. [5]

    Daca-Alvarez M, Manzotti C, Zaffalon D et al.. “Accuracy and variability of locoregional staging in T1 rectal cancer: nationwide multicentre cohort study.” BJS open (2025). PMID: 41914767 ↗

    L2bCOHORTCited in: Definition, Synonyms, and Classification, Diagnosis and Workup, Prognosis and Long-term Outcomes, Prevention and Screening
  6. [6]

    Tsokkou S, Konstantinidis I, Chatzikomnitsa P et al.. “The Molecular Signature of Early-Onset Colorectal Cancer Liver Metastases: Distinct Biology and Clinical Challenges.” International journal of molecular sciences (2026). PMID: 41977468 ↗

    L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification, Pathophysiology and Molecular Biology
  7. [7]

    Nemoto D, Togashi K, Zhu X et al.. “Artificial Intelligence-Based Prediction of Invasion Depth in Colorectal Cancer via Endoscopic Imaging (With Video): A Narrative Review.” Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society (2026). PMID: 41859770 ↗

    L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification
  8. [8]

    Cabitza VS, Capponi PC, Brusa I et al.. “Colorectal Cancer: A Landscape of New Potential Radiopharmaceuticals.” Molecular diagnosis & therapy (2026). PMID: 41807884 ↗

    L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification
  9. [9]

    Xie H, Xu N, Wei L et al.. “The prognostic value of the albumin/neutrophil-to-lymphocyte ratio in colorectal cancer patients: a retrospective cohort study.” Frontiers in oncology (2026). PMID: 41971429 ↗

    L2bCOHORTCited in: Definition, Synonyms, and Classification
  10. [10]

    Shi X, Tian G, Zhou C et al.. “Albumin and neutrophil combined prognostic grade for predicting overall survival in colorectal cancer: a retrospective cohort study.” Frontiers in oncology (2026). PMID: 41907620 ↗

    L2bCOHORTCited in: Definition, Synonyms, and Classification
  11. [11]

    Liu B, He H, Guan X et al.. “Clinicopathological characteristics and prognosis of patients with mucinous adenocarcinoma originating from the left colon, right colon, or rectum: a nationwide retrospective study in China.” Journal of gastrointestinal oncology (2026). PMID: 41816592 ↗

    L2bCOHORTCited in: Definition, Synonyms, and Classification
  12. [12]

    Rosenbaum W, Rubio Garcia M, Löfgren-Burström A et al.. “Full-length 16S rRNA nanopore sequencing enables species resolution of Fusobacterium associated with colorectal cancer.” Gut microbes (2026). PMID: 41963777 ↗

    L5OTHERCited in: Definition, Synonyms, and Classification
  13. [13]

    Pan AY, Kakavand H, Sioson L et al.. “A Critical Examination of the Changes Proposed by the AJCCCCEP for the AJCC 9th Edition Colorectal Cancer Staging System.” The American journal of surgical pathology (2026). PMID: 41957954 ↗

    L5OTHERCited in: Definition, Synonyms, and Classification
  14. [14]

    Yin Y, Sun Z, Deng X et al.. “Integration of deep learning and radiomic features from multiplex immunohistochemistry images for reproducible Multi-Outcome prediction in a Multi-Center study of colorectal cancer.” International journal of medical informatics (2026). PMID: 41955913 ↗

    L5OTHERCited in: Definition, Synonyms, and Classification, Prognosis and Long-term Outcomes
  15. [15]

    Fournier E, Schaffar R, Staehelin K et al.. “Rising early-onset colorectal cancer in Switzerland despite declining incidence in older adults: A nationwide population-based study, 1980-2021.” European journal of cancer (Oxford, England : 1990) (2026). PMID: 41946179 ↗

    L5OTHERCited in: Definition, Synonyms, and Classification
  16. [16]

    Ögren JÅ, Ekström J, Rameika N et al.. “Composite proteomic and metabolomic plasma biomarkers for detection of colorectal, lung and ovarian cancers.” Molecular cancer (2026). PMID: 41943016 ↗

    L5OTHERCited in: Definition, Synonyms, and Classification
  17. [17]

    McSorley ST, Burton P, Chantler D et al.. “Faecal haemoglobin-based referral and investigation prioritisation is associated with colorectal cancer-specific survival in symptomatic patients: a retrospective observational study.” British journal of cancer (2026). PMID: 41927996 ↗

    L5OTHERCited in: Definition, Synonyms, and Classification
  18. [18]

    Zohar K, Strecker M, Wartmann T et al.. “Globo-H diagnostic stratification and identification of DUSP14 as a candidate target in colorectal cancer.” International journal of cancer (2026). PMID: 41922912 ↗

    L5OTHERCited in: Definition, Synonyms, and Classification
  19. [19]

    Lv Y, Wang F, Shen Y et al.. “Redefining the role of carbon nanoparticles in colorectal cancer surgery: From lymph node yield to diagnostic paradox.” European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology (2026). PMID: 41921381 ↗

    L5OTHERCited in: Definition, Synonyms, and Classification
  20. [20]

    Nnene K, Nagar B, Boutall A et al.. “Treatment cost of colon cancer at a South African tertiary academic hospital.” Journal of cancer policy (2026). PMID: 41903647 ↗

    L5OTHERCited in: Definition, Synonyms, and Classification
  21. [21]

    Chen X, Liu C, Liao H. “Risk of high-grade infections in colorectal cancer patients treated with anti-EGFR monoclonal antibodies: a meta-analysis of randomized controlled trials.” Frontiers in oncology (2026). PMID: 41959919 ↗

    L1aSR_MA_RCTCited in: Epidemiology and Risk Factors, Management: Systemic and Radiation Therapy
  22. [22]

    Li G, Zhang W, Wang J et al.. “Prognostic role of statins in colorectal cancer: a systematic review and meta-analysis.” Frontiers in oncology (2026). PMID: 41930205 ↗

    L2aSR_OBSCited in: Epidemiology and Risk Factors
  23. [23]

    Zhou Y, Sang S, Yuan M et al.. “Effects of transcutaneous auricular vagus nerve stimulation on perioperative anxiety in patients undergoing laparoscopic colorectal cancer surgery: a study protocol for a double-blind, prospective, single-centre, randomised controlled trial.” BMJ open (2026). PMID: 41942155 ↗

    L2bTRIAL_NONRANDOMCited in: Epidemiology and Risk Factors, Diagnosis and Workup, Landmark Trials and Key Evidence
  24. [24]

    Cairat M, Olivier E, Neau J et al.. “Systemic glucocorticoid use and risk of site-specific cancers: a methodological systematic review of observational studies.” Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology (2026). PMID: 41931525 ↗

    L2aSR_OBSCited in: Epidemiology and Risk Factors
  25. [25]

    Liu X, Shuai J, Wang D et al.. “Incidence, risk factors, and a predictive nomogram for stoma-site incisional hernia after ileostomy reversal: A retrospective study.” Hernia : the journal of hernias and abdominal wall surgery (2026). PMID: 41995917 ↗

    L2bCOHORTCited in: Epidemiology and Risk Factors, Diagnosis and Workup, Prognosis and Long-term Outcomes
  26. [26]

    Charalambidi M, Hukkinen T, Kaprio T et al.. “Demographic and Clinical Characteristics of Early-Onset Colorectal Cancer in Sweden and Finland: A Multicentre Retrospective Cohort Study Over Three Decades.” Journal of surgical oncology (2026). PMID: 41928416 ↗

    L2bCOHORTCited in: Epidemiology and Risk Factors
  27. [27]

    Khan AA, Hasan F, Marsool MDM et al.. “Enhanced adenoma detection with Endocuff Vision: a GRADE assessed systematic review and meta-analysis.” Clinical endoscopy (2026). PMID: 41956736 ↗

    L2aSR_OBSCited in: Epidemiology and Risk Factors, Prevention and Screening
  28. [28]

    Zhang X, Wang P, Yu M et al.. “[Effect of electroacupuncture on intestinal function after laparoscopic colorectal cancer surgery].” Zhongguo zhen jiu = Chinese acupuncture & moxibustion (2026). PMID: 41987441 ↗

    L1bRCTCited in: Epidemiology and Risk Factors, Diagnosis and Workup
  29. [29]

    Jiang Y, Pu Y, Huang Z et al.. “Clonal tracing of rare anal metastasis in esophageal squamous cell carcinoma: a case report with whole-exome sequencing and multimodal therapy.” Frontiers in immunology (2026). PMID: 41972165 ↗

    L4CASE_REPORTCited in: Epidemiology and Risk Factors
  30. [30]

    Wang J, Yang Y, Yang X et al.. “The effectiveness of innovative educational techniques based on the Transtheoretical Model on the self-care ability of patients with colorectal cancer undergoing ostomy: A randomized controlled trial.” International journal of nursing sciences (2026). PMID: 41938003 ↗

    L1bRCTCited in: Epidemiology and Risk Factors
  31. [31]

    Lal A, Mudford E, Merga BT et al.. “Long-Term Health and Economic Impacts of COVID-19 Disruptions on Bowel Cancer Inequalities in Victoria, Australia: A Modelling Study.” Cancer medicine (2026). PMID: 41992350 ↗

    L5OTHERCited in: Epidemiology and Risk Factors, Diagnosis and Workup, Prevention and Screening
  32. [32]

    Moeckli B, Rocha M, Wassmer CH et al.. “Maternal obesity and the intergenerational risk of cancer: Epidemiologic evidence and mechanistic insights.” Cancer epidemiology (2026). PMID: 41990710 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Etiology and Triggering Factors
  33. [33]

    Alatise O, Doyle A, Mohammed T et al.. “A Pilot Randomized Cross-Over Trial Focused on Colonoscopy Skill Acquisition Using High Fidelity Versus Low Fidelity Simulators in Nigeria.” Journal of surgical education (2026). PMID: 41990515 ↗

    L5OTHERCited in: Epidemiology and Risk Factors, Prevention and Screening
  34. [34]

    Guimarães ACS, Rodrigues LLS, Campos LB et al.. “Beyond Human Papillomavirus (HPV): Detection of EBV and Polyomaviruses in Cervical and Anal Samples.” Journal of medical virology (2026). PMID: 41989205 ↗

    L5OTHERCited in: Epidemiology and Risk Factors, Diagnosis and Workup
  35. [35]

    Zhang D, Tao P, Li J et al.. “Targeting PKM2-dependent glycolysis reprogrammes monocytes into Cadm1+ macrophages to promote mucosal repair and attenuate colitis progression.” Gut (2026). PMID: 41986135 ↗

    L5OTHERCited in: Epidemiology and Risk Factors
  36. [36]

    Leja M, Ražuka-Ebela D, Tepes B et al.. “Overview of Gastric Cancer Prevention Initiatives in Europe.” Helicobacter (2026). PMID: 41981861 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Diagnosis and Workup, Prevention and Screening
  37. [37]

    Rifkin S, Anderson SM, Chen X et al.. “Association between Clostridioides difficile Test Positivity and Colorectal Cancer Incidence in a Multisite Hospital-Based Retrospective Cohort Analysis.” Cancer research communications (2026). PMID: 41975657 ↗

    L5OTHERCited in: Epidemiology and Risk Factors
  38. [38]

    Shin JK, Kim HC, Lee WY et al.. “Calibrated Absolute Risk of Lymph-Node-Metastasis After Non-curative Endoscopic Resection of pT1 Colorectal Cancer.” Annals of surgical oncology (2026). PMID: 41973291 ↗

    L5OTHERCited in: Epidemiology and Risk Factors
  39. [39]

    Hüneburg R, Gieffers-Löwen J, Aretz S et al.. “Longitudinal Surveillance of Gastric Polyposis in Familial Adenomatous Polyposis: Incidence, Progression, and Endoscopic Outcomes.” United European gastroenterology journal (2026). PMID: 41972342 ↗

    L5OTHERCited in: Epidemiology and Risk Factors, Diagnosis and Workup
  40. [40]

    Zhang B, Zhao Z, Yin P et al.. “Benchmarking progress in cause-specific cancers in China: a nationwide analysis of premature mortality from 1990 to 2023.” The Lancet regional health. Western Pacific (2026). PMID: 41970458 ↗

    L5OTHERCited in: Epidemiology and Risk Factors
  41. [41]

    Anderson SM, Cing Z, Drewes JL et al.. “Clostridioides difficile Detection in a Human CRC Cohort.” Open forum infectious diseases (2026). PMID: 41969757 ↗

    L5OTHERCited in: Epidemiology and Risk Factors
  42. [42]

    Wullaert L, van Leeuwen L, de Weerd V et al.. “Presurgical levels of circulating tumour DNA in patients with resectable chemotherapy-naïve colorectal liver metastases: association with multiorgan recurrence and survival in the MIRACLE cohort.” The British journal of surgery (2026). PMID: 41967049 ↗

    L5OTHERCited in: Epidemiology and Risk Factors, Prognosis and Long-term Outcomes
  43. [43]

    Zhang HX, Xu WJ, Jiang YX et al.. “Pyroptosis as a double-edged sword in colorectal cancer: Molecular mechanisms and therapeutic opportunities.” Apoptosis : an international journal on programmed cell death (2026). PMID: 41966661 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors
  44. [44]

    Piovani D, Figlioli G, Nikolopoulos GK et al.. “Global, regional, and national burden of colorectal cancer attributable to central obesity: a population attributable fraction analysis.” BMC medicine (2026). PMID: 41963940 ↗

    L5OTHERCited in: Epidemiology and Risk Factors
  45. [45]

    Schootman M, Li C, Peng C et al.. “Poverty and Mortality Risk in Patients With Colorectal Cancer.” JAMA network open (2026). PMID: 41961497 ↗

    L5OTHERCited in: Epidemiology and Risk Factors
  46. [46]

    Seum T, Mandic M, Safizadeh F et al.. “At what age should people with obesity start colorectal cancer screening?” International journal of cancer (2026). PMID: 41957948 ↗

    L5OTHERCited in: Epidemiology and Risk Factors
  47. [47]

    Gupta S, Liu L, Demb J et al.. “Colorectal Cancer and Mortality Risk Among Older Adults With vs Without Adenoma on Prior Colonoscopy.” JAMA (2026). PMID: 41954928 ↗

    L5OTHERCited in: Epidemiology and Risk Factors, Prevention and Screening
  48. [48]

    Seitz E, Tsai YY, Sanz-Pamplona R et al.. “Sex differences in the colorectal tumor-associated T cell responses.” Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology (2026). PMID: 41949638 ↗

    L5OTHERCited in: Epidemiology and Risk Factors
  49. [49]

    Corli O, Caldirola L, Galli F et al.. “Analgesic efficacy in women and men with cancer pain, treated with strong opioids: are there differences?” BMJ oncology (2026). PMID: 41948194 ↗

    L5OTHERCited in: Epidemiology and Risk Factors
  50. [50]

    van Roermund NS, Angerilli V, Nagtegaal ID et al.. “Prevalence and characteristics of sessile serrated lesions with dysplasia in Dutch fecal immunochemical test-positive screenees.” Endoscopy (2026). PMID: 41946470 ↗

    L5OTHERCited in: Epidemiology and Risk Factors, Prevention and Screening
  51. [51]

    Santos I, Liberal J, Teixeira P et al.. “The Role of the Gut Microbiome in Clinical Outcomes of Colorectal Cancer: A Systematic Review (2020-2025).” Oncology research (2026). PMID: 41799504 ↗

    L2aSR_OBSCited in: Etiology and Triggering Factors
  52. [52]

    Tustumi F, Park A, Nakamura ET et al.. “Safety and efficacy of chemoprevention for familial adenomatous polyposis: a systematic review and meta-analysis.” Annals of coloproctology (2026). PMID: 41802305 ↗

    L2aSR_OBSCited in: Etiology and Triggering Factors
  53. [53]

    Chen Y, Wang YT, Hu JY et al.. “Modulating the gut microbiota to enhance immune checkpoint inhibitor efficacy in colorectal cancer: mechanisms, therapeutic strategies, and clinical perspectives.” Gut microbes (2026). PMID: 41981741 ↗

    L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors, Pathophysiology and Molecular Biology, Management: Systemic and Radiation Therapy
  54. [54]

    Engin ED, Engin AB, Engin A. “Immune Evasion of Helicobacter pylori and Extra-Gastric Cancer Risk.” Journal of gastroenterology and hepatology (2026). PMID: 41972361 ↗

    L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors
  55. [55]

    Wuyi W, Tao P. “Microbe-driven immune suppression in colorectal cancer: the Fusobacterium nucleatum playbook.” Frontiers in immunology (2026). PMID: 41958661 ↗

    L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors, Management: Systemic and Radiation Therapy
  56. [56]

    Cummings LC, Freedman SD. “Increased gastrointestinal cancer risk in cystic fibrosis: Screening, prevention, and future directions.” Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society (2026). PMID: 41927358 ↗

    L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors, Prevention and Screening
  57. [57]

    Neufert C, Neurath MF. “Pathophysiology of colitis-associated colorectal cancer.” Nature reviews. Gastroenterology & hepatology (2026). PMID: 41922722 ↗

    L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors
  58. [58]

    Loaiza-Bonilla A, Leyfman Y, Cortiana V et al.. “Defining a Multi-Omic, AI-Enabled Stool Screening Paradigm for Colorectal Cancer: A Consensus Framework for Clinical Translation.” Cancers (2026). PMID: 41899514 ↗

    L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors
  59. [59]

    Li SWL, Au OTH, Lau EYT et al.. “Interplay Between Gut Microbiota and Cholesterol Metabolism in Colorectal Cancer.” International journal of molecular sciences (2026). PMID: 41898417 ↗

    L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors
  60. [60]

    Žukauskaitė K, Rauduvytė K, Baušys A et al.. “Surgery and the Gastrointestinal Microbiome in Cancer: Bidirectional Impacts and Therapeutic Opportunities - a Narrative Review.” Surgical oncology (2026). PMID: 41895157 ↗

    L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors
  61. [61]

    Khalil M, Baffy G, JohnBritto JS et al.. “Potential far-reaching metabolic consequences of cholecystectomy.” European journal of clinical investigation (2026). PMID: 41888988 ↗

    L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors
  62. [62]

    Sun S, Long F, Su B et al.. “The gut microbiome in colorectal anastomotic leakage: from mechanisms to precision.” Frontiers in medicine (2026). PMID: 41877779 ↗

    L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors
  63. [63]

    Dalamaga M, Rozani S, Petropoulou D. “Why Is Colorectal Cancer Occurring Earlier? Metabolic Dysfunction, Underrecognized Carcinogens, and Emerging Controversies.” Current obesity reports (2026). PMID: 41857189 ↗

    L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors, Pathophysiology and Molecular Biology
  64. [64]

    Fujiyoshi K, Sudo T, Shimamura S et al.. “A paradigm shift in genetic predisposition to colorectal cancer: the impact of germline multigene panel testing on diagnosis and management.” International journal of clinical oncology (2026). PMID: 41840140 ↗

    L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors
  65. [65]

    Li X, Wang Q, Yuan Q et al.. “The intratumoral microbiome in colorectal cancer: origins, microenvironmental interactions, and new horizons in precision medicine.” Frontiers in immunology (2026). PMID: 41836398 ↗

    L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors
  66. [66]

    Salazar-Ulbrich N, Haro-Solis D, Aguayo F et al.. “Genotoxic Bacteria and Oncogenic Viruses in Colorectal Cancer: Evidence, Gaps, and a Proposed Interaction Model.” International journal of molecular sciences (2026). PMID: 41828495 ↗

    L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors, Pathophysiology and Molecular Biology
  67. [67]

    Cataldi C, Karaoğlan BB, Liotta E et al.. “Decoding Immunotherapy Response in Colorectal Cancer: Translational Insights Beyond MSI.” Cancers (2026). PMID: 41827785 ↗

    L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors, Pathophysiology and Molecular Biology
  68. [68]

    Houlston RS, Dunlop MG. “Colonoscopy surveillance in Lynch syndrome: what it prevents and what it does not.” Journal of medical genetics (2026). PMID: 41825943 ↗

    L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors
  69. [69]

    Huo T, Huang X, Liao J et al.. “The bidirectional effects and mechanisms of the oral and gut microbiomes: a narrative review.” Frontiers in immunology (2026). PMID: 41808841 ↗

    L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors
  70. [70]

    Campos FG, Martinez CAR, Moura RN et al.. “Pouch cancer in familial adenomatous polyposis. Incidence, risk factors and literature review: a propos of three rare cases.” Arquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of digestive surgery (2026). PMID: 41983869 ↗

    L4CASE_REPORTCited in: Etiology and Triggering Factors, Supportive Care and Complication Management
  71. [71]

    Hashimoto H, Koda H, Nakajima K et al.. “Appendiceal Goblet Cell Adenocarcinoma With Mismatch Repair Deficiency and Microsatellite Instability-High Status: A Novel Molecular Signature Guiding Immuno-Oncology Strategy.” Pathology international (2026). PMID: 41872678 ↗

    L4CASE_REPORTCited in: Etiology and Triggering Factors, Pathophysiology and Molecular Biology
  72. [72]

    Chelluri R, Kovell S, Montanaro F et al.. “Upper tract urothelial carcinoma associated with Lynch syndrome.” Current opinion in oncology (2026). PMID: 41920568 ↗

    L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors, Pathophysiology and Molecular Biology
  73. [73]

    Han JY, Kim MJ, Park JW et al.. “Gut microbiome in colorectal cancer: recent advances and clinical implications.” Annals of coloproctology (2026). PMID: 41802308 ↗

    L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors
  74. [74]

    Wang X, Wei M, Yi Y et al.. “Elephant-derived Bacillus licheniformis modulates immune cells shedding light on cancer resistance.” Frontiers in microbiology (2026). PMID: 41994282 ↗

    L5OTHERCited in: Etiology and Triggering Factors
  75. [75]

    Park SB, Koo HS, Kim DS et al.. “A Clinicopathologic, Molecular, and Prognostic Comparison Between Early- and Late-Onset Colorectal Cancer in Korea: A Single-Center Retrospective Cohort Study.” Journal of clinical medicine (2026). PMID: 41827154 ↗

    L2bCOHORTCited in: Pathophysiology and Molecular Biology
  76. [76]

    Nikolouzakis TK, Souglakos J, Kantidakis EE et al.. “Metastatic Odyssey: Decoding the Genomic Journey from Primary Colorectal Cancer to Disseminated Disease.” Cancers (2026). PMID: 41976285 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Molecular Biology, Prognosis and Long-term Outcomes
  77. [77]

    Kendsersky ND, Erlick MR, Chen EY et al.. “The Evolving Role for Repeat Molecular Testing in Metastatic Colorectal Cancer.” Cancers (2026). PMID: 41899608 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Molecular Biology
  78. [78]

    Aktar S, Masoudi M, Moti D et al.. “Genetic Alterations Involved in Immune Escape Mechanisms of Circulating Tumour Cells in Colorectal Carcinogenesis.” Cancer medicine (2026). PMID: 41834250 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Molecular Biology
  79. [79]

    Zhao Y, Sui JF, Wu DN et al.. “Immuno-neural mechanisms in gastrointestinal tumorigenesis: bridging inflammation, neural regulation, and therapeutic innovation.” Frontiers in immunology (2025). PMID: 41799687 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Molecular Biology
  80. [80]

    Abbas H, Ahmed H, Shuja H et al.. “Comparative efficacy and safety of nivolumab-based combination therapies (with ipilimumab or binimetinib) in patients with microsatellite-stable and microsatellite-instability-high metastatic colorectal cancer: a systematic review and meta-analysis.” Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2026). PMID: 41934582 ↗

    L2aSR_OBSCited in: Pathophysiology and Molecular Biology
  81. [81]

    Gu F, Chen Z, Lim X et al.. “Chinese Herbal Medicine in Ulcerative Colitis-Associated Carcinogenesis Treatment: Mechanisms, Progress, and Future Directions.” Drug design, development and therapy (2026). PMID: 41908932 ↗

    L2aSR_OBSCited in: Pathophysiology and Molecular Biology
  82. [82]

    Xiong C, Wang W, Cha X et al.. “Pathological complete response following immunotherapy in dMMR/MSI-H ascending colon primary squamous cell carcinoma: a case report.” Frontiers in immunology (2026). PMID: 41958654 ↗

    L4CASE_REPORTCited in: Pathophysiology and Molecular Biology, Diagnosis and Workup, Management: Systemic and Radiation Therapy, Prognosis and Long-term Outcomes
  83. [83]

    Bai L, Yan X, Wang Z et al.. “The Dual Role of DNA Hypermethylation and Hypomethylation in Colorectal and Gastric Tumorigenesis: Mechanisms and Non-Invasive Biomarker.” Frontiers in bioscience (Landmark edition) (2026). PMID: 41914278 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Molecular Biology
  84. [84]

    Whitmer R, Sepulveda J, Gandhi J et al.. “Biomarkers in Colorectal Cancer: Clinically Relevant Diagnostic and Prognostic Molecular Features, and the Future of Precision Medicine.” Journal of personalized medicine (2026). PMID: 41893000 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Molecular Biology
  85. [85]

    Kim SY. “Immunotherapy for microsatellite-stable colorectal cancer: overcoming resistance and exploring novel therapeutic strategies.” Annals of coloproctology (2026). PMID: 41802306 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Molecular Biology
  86. [86]

    Iglesias Coma M, Badia-Ramentol J, Martinez-Ciarpaglini C et al.. “Stromal biomarker-based framework for identifying pMMR/MSS and dMMR/MSI colorectal cancers with poor outcomes and limited benefit from immunotherapy.” Gut (2026). PMID: 41980760 ↗

    L5OTHERCited in: Pathophysiology and Molecular Biology
  87. [87]

    Nasca V, Ambrosini M, Taieb J et al.. “Mucinous histology and resistance to immune checkpoint blockade in patients with microsatellite instability-high metastatic colorectal cancer.” The oncologist (2026). PMID: 41978558 ↗

    L5OTHERCited in: Pathophysiology and Molecular Biology
  88. [88]

    Xu T, Xie X, Gu X et al.. “Combined RAS and SMAD4 Mutations and Microsatellite Instability Predict Outcomes in Colorectal Lung Metastases Treated with Image-Guided Thermal Ablation.” Annals of surgical oncology (2026). PMID: 41975044 ↗

    L5OTHERCited in: Pathophysiology and Molecular Biology, Diagnosis and Workup
  89. [89]

    Li X, Xie M, Kang JX et al.. “Bifidobacterium catenulatum boosts anti-PD-1 efficacy in microsatellite stable colorectal cancer via activating CD8+ T cells.” Gut (2026). PMID: 41956809 ↗

    L5OTHERCited in: Pathophysiology and Molecular Biology
  90. [90]

    Ma M, Wang M, Yang Y et al.. “PVT1-104aa derived from the 8q24 gene desert promotes colorectal cancer tumorigenesis.” Clinical and translational medicine (2026). PMID: 41952439 ↗

    L5OTHERCited in: Pathophysiology and Molecular Biology
  91. [91]

    Ambrosini M, Gallois C, Gandini A et al.. “From clusters to clinic: An 8-gene signature combined with mucinous component stratifies benefit of anti-CTLA-4 addition to anti-PD-1 in dMMR/MSI-H metastatic colorectal cancer.” European journal of cancer (Oxford, England : 1990) (2026). PMID: 41950572 ↗

    L5OTHERCited in: Pathophysiology and Molecular Biology
  92. [92]

    Han K, Zhu C, Xu Z et al.. “A CT-based model integrating deep learning features radiomics and body composition for preoperative prediction of microsatellite instability in colorectal cancer: a multicenter study.” European journal of radiology (2026). PMID: 41935453 ↗

    L5OTHERCited in: Pathophysiology and Molecular Biology
  93. [93]

    Walden D, Batalini F, Eslinger C et al.. “Survival in Patients With Low Expression of Wild-Type Homologous Recombination Genes: Refining the Homologous Recombination Paradigm in Colorectal Cancer.” JCO precision oncology (2026). PMID: 41931743 ↗

    L5OTHERCited in: Pathophysiology and Molecular Biology, Management: Systemic and Radiation Therapy
  94. [94]

    Yang X, Zhang T, Sun H et al.. “Hsa-miR-99a deficiency contributes to MSI-H colorectal cancer progression by activating the mTOR pathway and inducing Th1/Th2 imbalance.” Frontiers in immunology (2026). PMID: 41924263 ↗

    L5OTHERCited in: Pathophysiology and Molecular Biology
  95. [95]

    Hong ZG, Xiao B, Zheng M et al.. “Risk and Management of Bowel Obstruction in Colorectal Cancer Patients Undergoing Immunotherapy: A Cross-Sectional Multicenter Study.” ImmunoTargets and therapy (2026). PMID: 41924184 ↗

    L5OTHERCited in: Pathophysiology and Molecular Biology
  96. [96]

    Zhan Q, Zhang S, Cao B et al.. “Single-Cell Multi-Tissue T Cell Clonal Dynamics Reveal Distinct Immune Coercion Landscapes in MSI and MSS Colorectal Cancer.” International journal of molecular sciences (2026). PMID: 41898550 ↗

    L5OTHERCited in: Pathophysiology and Molecular Biology, Management: Systemic and Radiation Therapy
  97. [97]

    Petäinen L, Väyrynen JP, Böhm J et al.. “dMMR prediction from colorectal cancer histopathology: Leveraging non-tumor and low-magnification regions.” Computer methods and programs in biomedicine (2026). PMID: 41875848 ↗

    L5OTHERCited in: Pathophysiology and Molecular Biology
  98. [98]

    Yanagisawa T, Okamoto T, Hayashi K. “Effectiveness of exercise interventions in patients with colorectal cancer during adjuvant chemotherapy: a systematic review and meta-analysis.” Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2026). PMID: 41860634 ↗

    L2aSR_OBSCited in: History and Physical Examination, Management: Systemic and Radiation Therapy, Supportive Care and Complication Management
  99. [99]

    Batrakoulis A, Perivoliotis K, Courneya KS et al.. “Comparative Efficacy of Various Exercise Types on Psychophysiological Outcomes in Colorectal Cancer Survivors: A Network Meta-Analysis.” Medicine and science in sports and exercise (2026). PMID: 41289064 ↗

    L2aSR_OBSCited in: History and Physical Examination
  100. [100]

    Ortega-Macías AG, Toro AV, Ghosh N et al.. “Addition of dexmedetomidine to anesthesia regimen reduces pain level after endoscopic submucosal dissection: A systematic review and meta analysis.” Journal of clinical anesthesia (2026). PMID: 41260073 ↗

    L2aSR_OBSCited in: History and Physical Examination
  101. [101]

    Varghese TS, Faithfull S, Frampton A et al.. “Association of patient factors and health-related quality of life with weight changes during chemotherapy for colorectal cancer: secondary analysis of the SCOT trial.” Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2026). PMID: 41711962 ↗

    L1bRCTCited in: History and Physical Examination
  102. [102]

    Li J, Jiang H, Song QL et al.. “Individualized intraoperative blood pressure control with norepinephrine reduces kidney injury biomarkers but not creatinine-defined acute kidney injury in older patients with hypertension undergoing major abdominal surgery: a single-center randomized controlled trial.” BMC anesthesiology (2026). PMID: 41491434 ↗

    L1bRCTCited in: History and Physical Examination
  103. [103]

    Koutoukidis DA, Jebb SA, Reynolds S et al.. “Preoperative Weight Loss in Patients With Excess Weight and Colorectal Cancer: The CARE Feasibility Randomized Clinical Trial.” JAMA network open (2025). PMID: 41359334 ↗

    L1bRCTCited in: History and Physical Examination
  104. [104]

    Wu Y, Tian B, Li L et al.. “Efficacy and safety of lidocaine versus sufentanil in patient-controlled intravenous analgesia after laparoscopic colorectal cancer surgery: a prospective, randomized, double-blind clinical trial.” BMC anesthesiology (2025). PMID: 41318377 ↗

    L1bRCTCited in: History and Physical Examination
  105. [105]

    Zhu X, Zhao S, Tang R et al.. “Effectiveness of Orem's self-care model nursing combined with nutritional intervention in postoperative patients with colorectal cancer.” Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2025). PMID: 41014371 ↗

    L1bRCTCited in: History and Physical Examination
  106. [106]

    Wang H, Wu C, Zhou S et al.. “Body mass index and early-onset colorectal cancer risk: a systematic review and cohort-based meta-analysis.” Scandinavian journal of gastroenterology (2026). PMID: 41603036 ↗

    L2aSR_OBSCited in: History and Physical Examination
  107. [107]

    Nihei S, Ujiie H, Saito K et al.. “A Prospective Comparison of Azilsartan and Amlodipine for Bevacizumab-induced Hypertension and Proteinuria in Colorectal Cancer.” In vivo (Athens, Greece) (2026). PMID: 41482380 ↗

    L1bRCTCited in: History and Physical Examination
  108. [108]

    Li M, Wang W, Yang Y et al.. “Efficacy of bupivacaine liposome transversus abdominis plane block in enhancing postoperative recovery following laparoscopic colorectal cancer resection.” Langenbeck's archives of surgery (2025). PMID: 41042339 ↗

    L1bRCTCited in: History and Physical Examination
  109. [109]

    Sun Y, Xu Z, Tang Y et al.. “Unveiling the impact of body mass index on surgical difficulty and oncological prognosis in low rectal cancer: post-hoc analysis of the LASRE trial.” International journal of colorectal disease (2025). PMID: 40844625 ↗

    L1bRCTCited in: History and Physical Examination
  110. [110]

    Beni R, Sekhon Inderjit Singh HK, Harper H et al.. “Evaluating the clinical use and safety of LumenEye in an outpatient colorectal clinic: a single-centre retrospective cohort study.” Techniques in coloproctology (2026). PMID: 41796404 ↗

    L2bCOHORTCited in: History and Physical Examination
  111. [111]

    Zhu C, Thong MSY, Doege D et al.. “Lifestyle factors and all-cause mortality in long-term cancer survivors: a population-based prospective cohort study.” European journal of epidemiology (2026). PMID: 41579289 ↗

    L2bCOHORTCited in: History and Physical Examination
  112. [112]

    Hjorth CF, Olsen MH, Ulrichsen SP et al.. “Body mass index and colorectal cancer recurrence and mortality: A nationwide cohort study in Denmark.” International journal of cancer (2026). PMID: 41273020 ↗

    L2bCOHORTCited in: History and Physical Examination
  113. [113]

    Shinozaki S, Watanabe J, Kanno T et al.. “Comparative Performance of Artificial Intelligence-Based Computer-Aided Detection Systems for Colorectal Polyps: A Systematic Review and Network Meta-Analysis.” Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society (2026). PMID: 41906553 ↗

    L2aSR_OBSCited in: Diagnosis and Workup, Prevention and Screening
  114. [114]

    Hsu WF, Kuo CY, Yen HH et al.. “Computer-Assisted Colonoscopy in High-Adenoma Detection Rate Settings in a High-Risk Population: A Randomized Clinical Trial.” JAMA network open (2026). PMID: 41984482 ↗

    L1bRCTCited in: Diagnosis and Workup, Prevention and Screening
  115. [115]

    Gerritse SL, van Meerten E, Duits AJ et al.. “The Keynote-177 Randomized Controlled Trial of First-line PD-1 Blockade for Microsatellite-High or Mismatch Repair-Deficient Advanced Colorectal Cancer: Potential Consequences of the Cross-Over Trial Design and Related Issues.” Cancer medicine (2026). PMID: 41980913 ↗

    L1bRCTCited in: Diagnosis and Workup, Supportive Care and Complication Management, Prognosis and Long-term Outcomes, Landmark Trials and Key Evidence
  116. [116]

    Majano Díaz L, Rodríguez de Santiago E, Núñez Rodríguez H et al.. “Temporary interruption versus maintenance of anticoagulation in polypectomy of colorectal lesions: study protocol for a multicentre randomised non-inferiority clinical trial POLYPHEM.” BMJ open (2026). PMID: 41916623 ↗

    L2bTRIAL_NONRANDOMCited in: Diagnosis and Workup, Landmark Trials and Key Evidence, Prevention and Screening
  117. [117]

    Marinho B, Velho G, Santos MD. “Cutaneous Manifestations as a Sentinel of Colorectal Cancer: A Case Report.” Journal of clinical medicine (2026). PMID: 41977089 ↗

    L4CASE_REPORTCited in: Diagnosis and Workup, Prevention and Screening
  118. [118]

    Günaltili M, Guliyev M, Birsin Z et al.. “Prognostic value of the pretreatment CA19-9/Albumin ratio in de novo metastatic colorectal cancer: A retrospective cohort study.” Medicine (2026). PMID: 41961685 ↗

    L2bCOHORTCited in: Diagnosis and Workup, Prognosis and Long-term Outcomes
  119. [119]

    Li ZF, Guo J, Sun C et al.. “Support vector machine-based MRI radiomics predict response to neoadjuvant therapy and progression-free-survival of Colorectal Liver Metastases patients.” Medical physics (2026). PMID: 41988745 ↗

    L5OTHERCited in: Diagnosis and Workup, Prognosis and Long-term Outcomes
  120. [120]

    Habibzadeh P, Sorkin J, Hsu D. “Association Between Red Blood Cell Distribution Width-To-Albumin Ratio and Breast, Colorectal, Lung, and Prostate Cancers.” Cancer medicine (2026). PMID: 41981727 ↗

    L5OTHERCited in: Diagnosis and Workup
  121. [121]

    Gurayah AA, An A, Kuchakulla M et al.. “Barriers to Health Care and Cancer Screening.” JAMA network open (2026). PMID: 41979877 ↗

    L5OTHERCited in: Diagnosis and Workup, Prevention and Screening
  122. [122]

    Xinmo F, Minghua B, Xu Q et al.. “Integrative Multiomics and Single-Cell Analyses Identify FKBP10 as a Predictor of Radiotherapy Outcome in Colorectal Cancer.” Human mutation (2026). PMID: 41969611 ↗

    L5OTHERCited in: Diagnosis and Workup, Prognosis and Long-term Outcomes
  123. [123]

    Ewing AP, Tounkara F, Lawrence WR et al.. “Colorectal Cancer Screening and Health-Related Social Needs in a National Sample of US Adults.” JAMA network open (2026). PMID: 41954935 ↗

    L5OTHERCited in: Diagnosis and Workup, Prevention and Screening
  124. [124]

    Nakajo S, Uemura M, Kusafuka H et al.. “Hypoxic CAF studies unveil PTHrP‑vitamin D‑RAS axis as pivotal in the CAF.” Oncology reports (2026). PMID: 41952490 ↗

    L5OTHERCited in: Diagnosis and Workup, Prognosis and Long-term Outcomes
  125. [125]

    Ferrera L, Martínez-Riveros H, Saña M et al.. “Concordance and Acceptability of Self- Vs. Clinician-Collected Anorectal Swabs for HPV Genotyping in Gay, Bisexual and Other Men Who Have Sex With Men in Metropolitan Barcelona.” Journal of medical virology (2026). PMID: 41949383 ↗

    L5OTHERCited in: Diagnosis and Workup, Prevention and Screening
  126. [126]

    Klausch T, Lissenberg-Witte BI, Coupé VMH. “A Bayesian Prevalence-Incidence Mixture Model for Screening Outcomes With Misclassification.” Statistics in medicine (2026). PMID: 41943977 ↗

    L5OTHERCited in: Diagnosis and Workup, Prevention and Screening
  127. [127]

    Townsend JS, Puckett MC, Coleman King SM et al.. “Knowledge, Symptom Awareness, and Referral Practices of Primary Care Providers in Early-Onset Colorectal Cancer.” Population health management (2026). PMID: 41943394 ↗

    L5OTHERCited in: Diagnosis and Workup, Prevention and Screening
  128. [128]

    Huang CY, Qiu XS, Lu SW et al.. “Lymph-vascular invasion affects the selection of time interval between surgery and postoperative chemotherapy in colon cancer.” Current problems in surgery (2026). PMID: 41942244 ↗

    L5OTHERCited in: Diagnosis and Workup, Management: Surgical and Local Therapies, Management: Systemic and Radiation Therapy, Prognosis and Long-term Outcomes
  129. [129]

    Yue Y, Sun Y, Huang Y et al.. “Safety and feasibility of combined transanal total mesorectal excision with delayed coloanal anastomosis in high-risk patients with low rectal cancer.” Techniques in coloproctology (2026). PMID: 41940995 ↗

    L5OTHERCited in: Diagnosis and Workup, Management: Surgical and Local Therapies, Prognosis and Long-term Outcomes
  130. [130]

    Grießhammer E, Bogovic N, Geissler EK et al.. “Compartment-specific GLUT1 patterns in colorectal liver metastases: invasive-margin GLUT1 associates with outcome in solitary disease.” Cancer immunology, immunotherapy : CII (2026). PMID: 41940986 ↗

    L5OTHERCited in: Diagnosis and Workup
  131. [131]

    Yu H, Reider L, Asenbaum U et al.. “Simultaneous microwave ablation and liver resection in patients with colorectal liver metastases.” HPB : the official journal of the International Hepato Pancreato Biliary Association (2026). PMID: 41934995 ↗

    L5OTHERCited in: Diagnosis and Workup
  132. [132]

    Dhar E, Kabir MA, Nadar DR et al.. “Exploring Machine Learning Approaches for Decision Support in Neoadjuvant Therapy of Locally Advanced Rectal Cancer.” Oncology research (2026). PMID: 41930174 ↗

    L5OTHERCited in: Diagnosis and Workup, Management: Systemic and Radiation Therapy
  133. [133]

    Gergő D, Tóth-Mészáros A, Schulze Wenning A et al.. “Efficacy and Safety of L-Menthol During Gastrointestinal Endoscopy-A Systematic Review and Meta-Analysis of Randomized Clinical Trials.” Journal of clinical medicine (2025). PMID: 40566063 ↗

    L2aSR_OBSCited in: Differential Diagnosis
  134. [134]

    Thorndal C, Schelde-Olesen B, Kaalby L et al.. “Colon capsule endoscopy compared with conventional colonoscopy in patients with colonic diverticulitis: a randomized controlled superiority trial on patient-reported outcomes.” Endoscopy (2026). PMID: 40907531 ↗

    L1bRCTCited in: Differential Diagnosis
  135. [135]

    De Silva R, Thomas JP, Murali N et al.. “The prevalence of nonmalignant gastrointestinal disease in patients with iron deficiency anemia: a systematic review and meta-analysis.” European journal of gastroenterology & hepatology (2026). PMID: 41784434 ↗

    L2aSR_OBSCited in: Differential Diagnosis
  136. [136]

    Shinagawa T, Okada S, Shiratori H et al.. “Statistics and epidemiology of inflammatory bowel disease-associated colorectal neoplasia.” International journal of clinical oncology (2026). PMID: 41721152 ↗

    L5REVIEW_NARRATIVECited in: Differential Diagnosis
  137. [137]

    Neurath MF. “New insights into Th9 cells in inflammatory bowel diseases.” Seminars in immunology (2026). PMID: 41406701 ↗

    L5REVIEW_NARRATIVECited in: Differential Diagnosis
  138. [138]

    Marafini I, Frascatani R, Colella M et al.. “Bromodomain-containing 4 as a therapeutic target in inflammatory bowel diseases and colorectal cancer.” Frontiers in pharmacology (2025). PMID: 41311847 ↗

    L5REVIEW_NARRATIVECited in: Differential Diagnosis
  139. [139]

    Lopetuso LR, Murgiano M, Mantuano E et al.. “The Molecular Landscape of Inflammation in Inflammatory Bowel Disease (IBD): Targets for Precision Medicine.” Biomedicines (2025). PMID: 41301831 ↗

    L5REVIEW_NARRATIVECited in: Differential Diagnosis
  140. [140]

    Wang Q, Meng Q, Chen Y et al.. “Interaction between gut microbiota and immunity in health and intestinal disease.” Frontiers in immunology (2025). PMID: 41293162 ↗

    L5REVIEW_NARRATIVECited in: Differential Diagnosis
  141. [141]

    Quagliariello V, Forte P, Ciappina G et al.. “Fusobacteriumnucleatum: Pathophysiological and Clinical Involvement in Inflammatory Bowel Diseases, Colorectal Cancer and Cardiovascular Diseases.” Cancers (2025). PMID: 41154402 ↗

    L5REVIEW_NARRATIVECited in: Differential Diagnosis
  142. [142]

    Triantaphyllopoulos KA, Ragia ND, Panagiotopoulou ME et al.. “Integrating Inflammatory and Epigenetic Signatures in IBD-Associated Colorectal Carcinogenesis: Models, Mechanisms, and Clinical Implications.” International journal of molecular sciences (2025). PMID: 41096771 ↗

    L5REVIEW_NARRATIVECited in: Differential Diagnosis
  143. [143]

    Martinelli M, Cascelli N, Bartolo O et al.. “The Molecular Landscape of Colorectal Laterally Spreading Tumors: From Endoscopic Subtypes to Molecular Targets.” International journal of molecular sciences (2025). PMID: 40943367 ↗

    L5REVIEW_NARRATIVECited in: Differential Diagnosis
  144. [144]

    Mariani L, Colombo F, Meuli S et al.. “The role of CT Colonography in the assessment of inflammatory bowel Diseases patients.” European journal of radiology (2025). PMID: 40913942 ↗

    L5REVIEW_NARRATIVECited in: Differential Diagnosis
  145. [145]

    Siyam K, Elessi K, Al-Dahdouh M et al.. “Characteristics and outcomes of patients undergoing colonoscopy in Gaza Strip hospitals: a retrospective study.” BMC gastroenterology (2026). PMID: 41652363 ↗

    L2bCOHORTCited in: Differential Diagnosis
  146. [146]

    Tran NT, Van Thai N, Khuyen NT et al.. “Aberrant TTF-1 expression in metastatic colorectal adenocarcinoma mimicking primary lung cancer: a case report and review of diagnostic pitfalls.” Diagnostic pathology (2025). PMID: 41310725 ↗

    L4CASE_REPORTCited in: Differential Diagnosis
  147. [147]

    Suárez M, Martínez R, Torres AM et al.. “Utility of Colonoscopy After Acute Colonic Diverticulitis.” Diagnostics (Basel, Switzerland) (2026). PMID: 41975762 ↗

    L5REVIEW_NARRATIVECited in: Differential Diagnosis
  148. [148]

    Tuynman JB, Yao H, Moolenaar LR et al.. “Transanal total mesorectal excision versus laparoscopic total mesorectal excision for mid and low rectal cancer (COLOR III): short-term outcomes of an international, multicentre, phase 3, randomised, controlled, non-inferiority trial.” The lancet. Gastroenterology & hepatology (2026). PMID: 41887239 ↗

    L1bRCTCited in: Management: Surgical and Local Therapies
  149. [149]

    Sinicrope FA, Ou FS, Arnold D et al.. “Atezolizumab plus FOLFOX for Stage III Mismatch Repair-Deficient Colon Cancer.” The New England journal of medicine (2026). PMID: 41880612 ↗

    L1bRCTCited in: Management: Surgical and Local Therapies, Management: Systemic and Radiation Therapy
  150. [150]

    Kitaguchi D, Forgione A, Innocenzi C et al.. “The role of complete mesocolic excision with central vascular ligation in colon cancer surgery: A systematic review and meta-analysis of prospective trials.” European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology (2026). PMID: 41774976 ↗

    L2aSR_OBSCited in: Management: Surgical and Local Therapies
  151. [151]

    Reali C, Borra P, Francis NK. “Quality assurance of surgical techniques for right colon cancer: Systematic review.” Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland (2026). PMID: 41891400 ↗

    L2aSR_OBSCited in: Management: Surgical and Local Therapies
  152. [152]

    Matsuda T, Nagatani Y, Funakoshi Y et al.. “Neoadjuvant FOLFOXIRI plus bevacizumab without radiotherapy for high-risk rectal cancer: multicentre phase II trial.” BJS open (2025). PMID: 41661200 ↗

    L2bTRIAL_NONRANDOMCited in: Management: Surgical and Local Therapies
  153. [153]

    Mohammed KB, Kahin M, Okasha AA et al.. “Comparative Efficacy of Robotic-Assisted Versus Laparoscopic Resection for Colorectal Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.” Cureus (2026). PMID: 41732636 ↗

    L1aSR_MA_RCTCited in: Management: Surgical and Local Therapies
  154. [154]

    Scardino A, Wolthuis A, Taffurelli G et al.. “Readmission rates and predictive factors in older patients undergoing colorectal cancer surgery: A multicenter European retrospective study.” European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology (2026). PMID: 41795429 ↗

    L2bCOHORTCited in: Management: Surgical and Local Therapies
  155. [155]

    Zaman O, Zaman S, Ebraheem M et al.. “Trans-anal minimally invasive surgery (TAMIS): Case series on short-term outcomes and systematic review of the literature.” The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland (2026). PMID: 41916806 ↗

    L2aSR_OBSCited in: Management: Surgical and Local Therapies, Prognosis and Long-term Outcomes
  156. [156]

    Al-Ihribat AR, Moqbel I, Oun A et al.. “Perioperative outcomes of robotic-assisted vs. conventional laparoscopy for colorectal cancer resection: a systematic review and meta-analysis.” Frontiers in surgery (2026). PMID: 41822113 ↗

    L2aSR_OBSCited in: Management: Surgical and Local Therapies
  157. [157]

    Liang J, Chen W, Yang J et al.. “Laparoscopic-assisted vs open surgery for synchronous colorectal cancer: a retrospective cohort study of short-term and long-term outcomes.” BMC gastroenterology (2026). PMID: 41851844 ↗

    L2bCOHORTCited in: Management: Surgical and Local Therapies
  158. [158]

    Butnari V, Mansuri A, Hanson M et al.. “Robotic sigmoid colectomy with intracorporeal anastomosis: IMV first approach-a video vignette.” Techniques in coloproctology (2026). PMID: 41896493 ↗

    L4CASE_REPORTCited in: Management: Surgical and Local Therapies
  159. [159]

    Johns J, Lekamalage B, Cribb B et al.. “Anastomotic leak rates between powered and non-powered circular staplers in left-sided colorectal resection; a retrospective cohort study.” The New Zealand medical journal (2026). PMID: 41610291 ↗

    L2bCOHORTCited in: Management: Surgical and Local Therapies
  160. [160]

    Kuliavas J, Marcinkeviciute K, Vaicekauskaite I et al.. “Increased Risk of Central Mesocolic Lymph Node Metastases in BRAF-Mutated Stage I-III Colon Cancer.” Journal of clinical medicine (2026). PMID: 41977067 ↗

    L5OTHERCited in: Management: Surgical and Local Therapies
  161. [161]

    Kapturkiewicz B, Kazanowski M, Lesiak P et al.. “Analysis of the impact of the learning curve and other factors on the duration of TaTME procedures.” Techniques in coloproctology (2026). PMID: 41917328 ↗

    L5OTHERCited in: Management: Surgical and Local Therapies
  162. [162]

    Efetov S, Perez R, Hompes R et al.. “A multinational pilot survey of clinical practice patterns in tumor-specific mesocolic excision and complete lymph node dissection for colorectal cancer.” International journal of clinical oncology (2026). PMID: 41870762 ↗

    L5OTHERCited in: Management: Surgical and Local Therapies
  163. [163]

    Chen WP, Li ZK, Lin L et al.. “The clinical effect and oncological results of preserving inferior mesenteric artery during laparoscopic complete mesocolic excision for patients with descending colon cancer: a propensity score-matched analysis.” Techniques in coloproctology (2026). PMID: 41838213 ↗

    L5REVIEW_NARRATIVECited in: Management: Surgical and Local Therapies
  164. [164]

    Lohsiriwat V, Kaenla E, Ovartchaiyapong P. “Enhanced Recovery After Surgery Versus Conventional Care in Simultaneous Colorectal Resection and Hepatectomy for Synchronous Colorectal Liver Metastases.” World journal of surgery (2026). PMID: 41831191 ↗

    L5OTHERCited in: Management: Surgical and Local Therapies
  165. [165]

    Dahlberg S, Vedin T, Syk I et al.. “Unplanned intensive care unit admission after elective colon cancer resection: population-based registry study.” BJS open (2025). PMID: 41802244 ↗

    L5OTHERCited in: Management: Surgical and Local Therapies
  166. [166]

    Chen YC, Chang TK, Su WC et al.. “Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Locally Advanced Rectal Cancer Treated with Neoadjuvant Concurrent Chemoradiotherapy and Robotic-Assisted Resection.” Oncology research (2026). PMID: 41799506 ↗

    L5OTHERCited in: Management: Surgical and Local Therapies
  167. [167]

    Chew C, Panesa A, Haq MU et al.. “Feasibility and outcomes of robotic colorectal cancer surgery in patients with high body mass index.” Techniques in coloproctology (2026). PMID: 41793538 ↗

    L5OTHERCited in: Management: Surgical and Local Therapies
  168. [168]

    Omura Y, Nakauchi M, Hiro J et al.. “Lateral lymph node dissection via robotic surgery: technical feasibility and patterns of lateral lymph node recurrence in rectal cancer.” Surgical oncology (2026). PMID: 41759372 ↗

    L5OTHERCited in: Management: Surgical and Local Therapies
  169. [169]

    Pretta A, Giampieri R, Ziranu P et al.. “Clinical characteristics and outcomes in patients with early-onset locally advanced rectal cancer.” Therapeutic advances in medical oncology (2026). PMID: 41743382 ↗

    L5OTHERCited in: Management: Surgical and Local Therapies
  170. [170]

    Slørdahl KS, Balto A, Guren MG et al.. “Patient reported outcomes after treatment for colon cancer - A nationwide study.” European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology (2026). PMID: 41722357 ↗

    L5OTHERCited in: Management: Surgical and Local Therapies
  171. [171]

    Bunjo Z, Seneviratne I, Murshed I et al.. “Statewide analysis of outcomes in patients with early-stage rectal cancer undergoing standard-of-care upfront resection.” European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology (2026). PMID: 41719784 ↗

    L5OTHERCited in: Management: Surgical and Local Therapies
  172. [172]

    Swilling AC, Chalise P, Al-Kasspooles M et al.. “Volume-Outcome Relationships in Total Mesorectal Excision Quality and Grading: A National Cancer Database Study.” Annals of surgical oncology (2026). PMID: 41703205 ↗

    L5OTHERCited in: Management: Surgical and Local Therapies
  173. [173]

    Jo MH, Kim HS, Chung SS et al.. “Single-incision robotic complete mesocolic excision for right-sided colon neoplasms: technical and oncologic feasibility.” Surgical endoscopy (2026). PMID: 41703038 ↗

    L5OTHERCited in: Management: Surgical and Local Therapies
  174. [174]

    Wang L, Li G, Lv Y et al.. “Optimization of artery-first approach in right-sided colon cancer CME: preoperative CTA assessment of MCA branching and MCV-Henle's trunk relationship.” World journal of surgical oncology (2026). PMID: 41699604 ↗

    L5OTHERCited in: Management: Surgical and Local Therapies
  175. [175]

    Ahluwalia AS, Ramesh H, Asad Z et al.. “Assessing the Association of Age and Preoperative Sodium Level on Colectomy Outcomes: An NSQIP Study.” The Journal of surgical research (2026). PMID: 41687140 ↗

    L5OTHERCited in: Management: Surgical and Local Therapies
  176. [176]

    Li Y, Han C, Tang J. “Neoadjuvant chemoradiotherapy with or without PD-1 inhibitors in MMR-proficient non-metastatic rectal cancer: a meta-analysis of randomized controlled trials.” Frontiers in immunology (2026). PMID: 41853263 ↗

    L1aSR_MA_RCTCited in: Management: Systemic and Radiation Therapy, Landmark Trials and Key Evidence
  177. [177]

    Arjona-Sánchez A, Gutiérrez-Calvo A, Segura-Sampedro JJ et al.. “Efficacy and safety of intraoperative hyperthermic intraperitoneal chemotherapy for locally advanced colorectal cancer (HIPECT4): final analysis of randomized clinical trial.” BJS open (2025). PMID: 41891861 ↗

    L1bRCTCited in: Management: Systemic and Radiation Therapy
  178. [178]

    Kito Y, Yamazaki K, Shoji H et al.. “Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer: WJOG9216G (RECAST).” European journal of cancer (Oxford, England : 1990) (2026). PMID: 41880871 ↗

    L1bRCTCited in: Management: Systemic and Radiation Therapy
  179. [179]

    Xicheng W, Yanhong D, Yanqiao Z et al.. “A Randomized Trial of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or FOLFIRI/Cetuximab in Chinese Patients With BRAFV600E Mutant Metastatic Colorectal Cancer: The NAUTICAL Study.” Cancer medicine (2026). PMID: 41852303 ↗

    L1bRCTCited in: Management: Systemic and Radiation Therapy, Supportive Care and Complication Management
  180. [180]

    Gregorc V, Majem M, Lo Russo G et al.. “Fulzerasib plus cetuximab in first-line KRASG12C-mutated non-small-cell lung cancer (KROCUS): a single-arm, multicentre, phase 1b/2 trial.” The Lancet. Oncology (2026). PMID: 41926959 ↗

    L2bTRIAL_NONRANDOMCited in: Management: Systemic and Radiation Therapy
  181. [181]

    Chibaudel B, Dourthe LM, André T et al.. “STRATEGIC-1: multiple-line, randomized, open-label GERCOR-PRODIGE-39 phase III trial in unresectable RAS/BRAF wild-type metastatic colorectal cancer.” Signal transduction and targeted therapy (2026). PMID: 41980919 ↗

    L1bRCTCited in: Management: Systemic and Radiation Therapy
  182. [182]

    Ding L, Peng L, Xu Z et al.. “Interpretable machine-learning prediction of severe myelosuppression in colorectal cancer patients receiving chemotherapy using XGBoost and SHAP: a retrospective study with a web-based calculator.” Frontiers in oncology (2026). PMID: 41939468 ↗

    L2bCOHORTCited in: Management: Systemic and Radiation Therapy
  183. [183]

    Qadri F, Afghan MK, Lutfi A et al.. “Molecular complete response to the RIN protocol (regorafenib, ipilimumab, and nivolumab) in a patient with advanced recurrent metastatic mismatch repair proficient/microsatellite stable (pMMR/MSS) rectal cancer.” Therapeutic advances in medical oncology (2026). PMID: 41883872 ↗

    L4CASE_REPORTCited in: Management: Systemic and Radiation Therapy
  184. [184]

    Cashin PH, Frühling P, Grönlund P et al.. “Preoperative chemotherapy in colorectal peritoneal metastatic disease - a real-world observational cohort study.” Pleura and peritoneum (2026). PMID: 41868813 ↗

    L2bCOHORTCited in: Management: Systemic and Radiation Therapy
  185. [185]

    Abbas N, Mourad M, Smaily H et al.. “EGFR Signaling in Colorectal Cancer: Novel Therapeutic Strategies, Predictive Biomarkers, and Counteracting Treatment Resistance.” International journal of molecular sciences (2026). PMID: 41977448 ↗

    L5REVIEW_NARRATIVECited in: Management: Systemic and Radiation Therapy
  186. [186]

    Yang W, Zhang J, Liang P et al.. “Irinotecan with trifluridine/tipiracil and bevacizumab for second-line metastatic colorectal cancer: a phase II multicenter study.” Signal transduction and targeted therapy (2026). PMID: 41956997 ↗

    L2bTRIAL_NONRANDOMCited in: Management: Systemic and Radiation Therapy
  187. [187]

    Wang Q, Liu Z, Jin K. “Natural Polymers Based Biocompatible Nanomedicines for Targeting Colon Cancer: Prospects and Challenges.” International journal of nanomedicine (2026). PMID: 41939211 ↗

    L5REVIEW_NARRATIVECited in: Management: Systemic and Radiation Therapy
  188. [188]

    Cives-Losada C, Soldani C, Polidoro MA et al.. “Understanding the Tumor Microenvironmental Mechanisms Driving Immunotherapy Resistance in Colorectal Cancer Liver Metastases.” Oncology research (2026). PMID: 41930154 ↗

    L5REVIEW_NARRATIVECited in: Management: Systemic and Radiation Therapy
  189. [189]

    Cao M, Alvarez J, Mitra R et al.. “IFNγ-induced antigen loss in chimeric antigen receptor-T cell therapy.” Frontiers in immunology (2026). PMID: 41924255 ↗

    L5OTHERCited in: Management: Systemic and Radiation Therapy
  190. [190]

    Funk MA, Heinemann V, Bücklein V et al.. “Gastric and Rectal Administration of Encorafenib with Targeted Chemotherapy against BRAF V600E-Mutant Rectal Cancer with Bowel Obstruction.” The oncologist (2026). PMID: 41920914 ↗

    L5OTHERCited in: Management: Systemic and Radiation Therapy
  191. [191]

    Kang W, Zhang Z, Li W et al.. “Breaching the immune-cold barrier in pMMR/MSS metastatic colorectal cancer: emerging strategies beyond standard care.” Frontiers in immunology (2026). PMID: 41909713 ↗

    L5REVIEW_NARRATIVECited in: Management: Systemic and Radiation Therapy
  192. [192]

    Wang F, Zhang Z, Chen J et al.. “Nanodynamic Therapy in Colorectal Cancer: Engineering Precision Immunotherapy and Multimodal Synergy.” International journal of nanomedicine (2026). PMID: 41907375 ↗

    L5REVIEW_NARRATIVECited in: Management: Systemic and Radiation Therapy
  193. [193]

    Wagner AD, Raeisi M, Rakez M et al.. “Sex differences in efficacy and toxicity of first-line treatment of metastatic colorectal cancer: An analysis of 18,041 patients in the ARCAD CRC database.” European journal of cancer (Oxford, England : 1990) (2026). PMID: 41903302 ↗

    L5OTHERCited in: Management: Systemic and Radiation Therapy
  194. [194]

    Kawczak P, Bączek T. “Molecular Targeting of EGFR, BRAF, and HER2 Signaling in Colorectal Cancer: Contemporary Advances with Panitumumab, Encorafenib, and Tucatinib.” Journal of clinical medicine (2026). PMID: 41899309 ↗

    L5REVIEW_NARRATIVECited in: Management: Systemic and Radiation Therapy
  195. [195]

    Yeh JH, Hsu CW, Shen CS et al.. “Save the injection needle for colorectal ESD: a multicenter feasibility study of the needleless injection technique using short-tip endoknife.” Techniques in coloproctology (2026). PMID: 41896390 ↗

    L5OTHERCited in: Management: Systemic and Radiation Therapy
  196. [196]

    Gao S, Liao X, He Y et al.. “The effectiveness of multimodal prehabilitation on functional capacity and clinical outcomes in patients undergoing elective laparoscopic colorectal cancer surgery: a systematic review of meta-analysis of randomized controlled trials.” Journal of cancer survivorship : research and practice (2026). PMID: 41872610 ↗

    L1aSR_MA_RCTCited in: Supportive Care and Complication Management
  197. [197]

    He Y, Yuan X, Gao S et al.. “Home-based multimodal prehabilitation before colorectal cancer surgery: a systematic review and meta-analysis.” Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2026). PMID: 41870618 ↗

    L2aSR_OBSCited in: Supportive Care and Complication Management
  198. [198]

    Lin Y, Tian D, He J et al.. “The invisible wall: experiences of social isolation in colorectal cancer patients with ostomy-a qualitative meta-synthesis.” Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2026). PMID: 41817765 ↗

    L2aSR_OBSCited in: Supportive Care and Complication Management
  199. [199]

    Xiaobing Y, Qidi L, Liyan L et al.. “The effect of thunder-fire moxibustion on cancer-related fatigue in patients with Qi stagnation and blood stasis type colorectal cancer undergoing chemotherapy: a randomized controlled trial.” Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2026). PMID: 41986533 ↗

    L1bRCTCited in: Supportive Care and Complication Management
  200. [200]

    Reeves J, Koh C, Smith AB et al.. “Acceptability and Feasibility of a Virtual Multimodal (P)Rehabilitation Programme for Gastrointestinal Cancer Patients: The PRIORITY-CONNECT 2 Pilot Randomised Controlled Trial.” Annals of surgical oncology (2026). PMID: 41832362 ↗

    L1bRCTCited in: Supportive Care and Complication Management
  201. [201]

    Kubo E, Satomi E, Mukohara T et al.. “Randomized Controlled Trial to Relieve Pain of Chemotherapy-Induced Peripheral Neuropathy by Magnetic Field: SMILE Study.” Cancers (2026). PMID: 41749832 ↗

    L1bRCTCited in: Supportive Care and Complication Management
  202. [202]

    Díaz-Sánchez C, Rodríguez-Muñoz PM, Navarro-López V et al.. “Impact of Ostomy on Quality of Life in Patients with Colorectal Cancer: A Systematic Review and Meta-Analysis.” Healthcare (Basel, Switzerland) (2026). PMID: 41753958 ↗

    L2aSR_OBSCited in: Supportive Care and Complication Management
  203. [203]

    Ben Kridis W, Aboturkia AM, Aqoup MO et al.. “Diet and Physical Activity Interventions to Improve Outcomes in Colorectal Cancer Survivors: A Multicenter Randomized Controlled Trial in North Africa.” JCO global oncology (2026). PMID: 41886719 ↗

    L1bRCTCited in: Supportive Care and Complication Management
  204. [204]

    Wang C, Nie L, Li X et al.. “Effects of combined dietary fiber and probiotic supplementation on gut microbiota, immune function, and clinical outcomes in patients with advanced colorectal cancer: a retrospective cohort study.” Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2026). PMID: 41823995 ↗

    L2bCOHORTCited in: Supportive Care and Complication Management
  205. [205]

    Peng W, Shi H, Fan L et al.. “Efficacy of a plant-based diet on FOLFOX chemotherapy-induced gastrointestinal toxicity in patients with colorectal cancer: study protocol for a multicentre, stratified, randomised controlled trial.” Trials (2026). PMID: 41772652 ↗

    L2bTRIAL_NONRANDOMCited in: Supportive Care and Complication Management
  206. [206]

    Addington C, Davies N, Howell P et al.. “Lived experiences of cancer care for people living with HIV who are treated for anal cancer: a scoping review.” BMJ open (2026). PMID: 41916622 ↗

    L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management
  207. [207]

    Noiret B, Perez RO, Conroy T et al.. “Disruptive Analysis of Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer: Clinical and Therapeutic Distinctions Between Low- and Mid-Rectal Cancers.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2026). PMID: 41791024 ↗

    L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management
  208. [208]

    Wu Y, Pang J, Li J et al.. “Curcumin for the Treatment of Inflammatory Bowel Disease: From Mechanism to Clinic.” The American journal of Chinese medicine (2026). PMID: 41757464 ↗

    L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management
  209. [209]

    Sokólska W, Gudowska-Sawczuk M, Orywal K. “Cytokines and Chemokines as Emerging Biomarkers and Therapeutic Targets in Colorectal Cancer-Narrative Review.” International journal of molecular sciences (2026). PMID: 41752132 ↗

    L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management
  210. [210]

    Chen H, Wang Q, Chen Y et al.. “Risk factors and prediction model for early high-output stoma after colorectal cancer surgery: A retrospective study.” Asia-Pacific journal of oncology nursing (2026). PMID: 41858760 ↗

    L2bCOHORTCited in: Supportive Care and Complication Management
  211. [211]

    Li Y, Zou D, Hu J et al.. “A multimodal neoadjuvant strategy incorporating PDT, RFA, and ICIs results in a notable pathological response and preservation of the sphincter in microsatellite stable low rectal cancer: A highly distinctive case report and literature review.” Photodiagnosis and photodynamic therapy (2026). PMID: 41833681 ↗

    L4CASE_REPORTCited in: Supportive Care and Complication Management
  212. [212]

    Pan S, Wang G. “Perioperative Systemic Stress Phenotypes Predict Immune Recovery Failure, Molecular Residual Disease, and Long-Term Outcomes After Colorectal Cancer Surgery: A Prospective Cohort Study.” World journal of surgery (2026). PMID: 41917719 ↗

    L2bCOHORTCited in: Prognosis and Long-term Outcomes
  213. [213]

    Burlaka A, Zemskov S, Rozhkova V et al.. “Laparoscopic versus open minor liver resections of colorectal cancer liver metastases in a state at war: A prospective cohort study.” Surgery open science (2026). PMID: 41971756 ↗

    L2bCOHORTCited in: Prognosis and Long-term Outcomes
  214. [214]

    Shan S, Fu S, Ma Z et al.. “Temporally Programmed and Laser-Triggered Immunomodulatory Hydrogel Enables Synergistic Wound Healing and Prevention of Postoperative Tumor Recurrence.” ACS applied materials & interfaces (2026). PMID: 41995291 ↗

    L5OTHERCited in: Prognosis and Long-term Outcomes
  215. [215]

    AlAwadhi HK, Chang NH, Jogendran M et al.. “Gastroenterology/Hepatology: What You May Have Missed in 2025.” Annals of internal medicine (2026). PMID: 41974014 ↗

    L5OTHERCited in: Prognosis and Long-term Outcomes
  216. [216]

    Moretto R, Studiale V, Hyun SW et al.. “Circulating tumor DNA dynamics in patients with liver-limited metastatic colorectal cancer resected after first-line systemic treatment.” Clinical cancer research : an official journal of the American Association for Cancer Research (2026). PMID: 41973053 ↗

    L5OTHERCited in: Prognosis and Long-term Outcomes
  217. [217]

    Machida E, Takamizawa Y, Takayanagi D et al.. “Microbiomic and immunogenic biomarkers of adjuvant chemotherapy efficacy in stage III colorectal cancer.” JNCI cancer spectrum (2026). PMID: 41965123 ↗

    L5OTHERCited in: Prognosis and Long-term Outcomes
  218. [218]

    Zhu G, Liu Y, Shi Y et al.. “Dissecting tumor heterogeneity in colorectal cancer: uncovering the role of BCL2L1+ cells through single-cell analysis.” Frontiers in immunology (2026). PMID: 41958675 ↗

    L5OTHERCited in: Prognosis and Long-term Outcomes
  219. [219]

    Aref AT, Pathan M, Habib R et al.. “Proteomics-Driven Risk Stratification in Stage III Colon Cancer: A Validated Prognostic Signature for Recurrence Prediction using three independent cohorts.” Clinical cancer research : an official journal of the American Association for Cancer Research (2026). PMID: 41954643 ↗

    L5OTHERCited in: Prognosis and Long-term Outcomes
  220. [220]

    Liu Z, Gao D, Martin T et al.. “Impact of Rural Hospital Closures on Survival Among Medicare Beneficiaries Diagnosed With Colorectal, Lung, Breast, and Prostate Cancer.” The Journal of rural health : official journal of the American Rural Health Association and the National Rural Health Care Association (2026). PMID: 41947577 ↗

    L5OTHERCited in: Prognosis and Long-term Outcomes
  221. [221]

    Wang J, Li Y, Liu X et al.. “Methylated Septin9 as an auxiliary biomarker for the diagnostic, recurrence monitoring and prognosis of colorectal cancer.” Clinica chimica acta; international journal of clinical chemistry (2026). PMID: 41941932 ↗

    L5OTHERCited in: Prognosis and Long-term Outcomes
  222. [222]

    Lu J, Wang R, Chong YY. “Effects of psychosocial interventions on cancer-related fatigue in patients with colorectal cancer: a systematic review and meta-analysis of randomised controlled trials.” Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2026). PMID: 41840094 ↗

    L1aSR_MA_RCTCited in: Landmark Trials and Key Evidence
  223. [223]

    Xun X, Wang R, Cheng Q et al.. “The Impact of Prehabilitation on Postoperative Outcomes in Colorectal Cancer: A Meta-Analysis of Randomized Controlled Trials.” Journal of the American Medical Directors Association (2026). PMID: 41698408 ↗

    L1aSR_MA_RCTCited in: Landmark Trials and Key Evidence
  224. [224]

    Blanchard-Cavagis ER, Abrahão Reis PC, Visani FLV et al.. “Adjuvant aspirin and Cyclooxygenase-2 inhibitors in resected, PIK3CA-mutated colorectal cancer: A systematic review and meta-analysis of randomized controlled trials.” Critical reviews in oncology/hematology (2026). PMID: 41621633 ↗

    L1aSR_MA_RCTCited in: Landmark Trials and Key Evidence
  225. [225]

    Li Y, Ho K, Lui TK et al.. “Comparison of Image-Enhanced Endoscopy Techniques for Colorectal Lesion Detection and Characterization: A Network Meta-Analysis of Randomized Controlled Trials.” The American journal of gastroenterology (2026). PMID: 41472621 ↗

    L1aSR_MA_RCTCited in: Landmark Trials and Key Evidence
  226. [226]

    Srinivasan A, Yi KM, Sharma D et al.. “Integrating multimodal prehabilitation into enhanced recovery after surgery programs (MPhERAS) for elderly patients: a systematic review and meta-analysis of randomized controlled trials and cohort studies.” Techniques in coloproctology (2025). PMID: 41455772 ↗

    L1aSR_MA_RCTCited in: Landmark Trials and Key Evidence
  227. [227]

    Mirza W, Iqbal H, Yasmin S et al.. “Indocyanine green fluorescence-guided perfusion vs. standard assessment to prevent clinical anastomotic leak after colorectal resection: a GRADE-assessed systematic review and meta-analysis of randomized controlled trials with site-specific subgroup analysis.” World journal of surgical oncology (2025). PMID: 41422225 ↗

    L1aSR_MA_RCTCited in: Landmark Trials and Key Evidence
  228. [228]

    Li T, Yin L, Li Y et al.. “Folate exposures and risk of colorectal cancer: an umbrella review of meta-analyses of observational studies and randomised controlled trials.” BMJ open (2025). PMID: 41314820 ↗

    L1aSR_MA_RCTCited in: Landmark Trials and Key Evidence
  229. [229]

    Garfinkle R, Balvardi S, Carmichael H et al.. “Outcomes reported in randomized controlled trials of rectal cancer treatment: A scoping review for the CORRECT initiative.” European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology (2026). PMID: 41564846 ↗

    L1bRCTCited in: Landmark Trials and Key Evidence
  230. [230]

    Zhang X, Zhou J, Geng J et al.. “Feasibility of ctDNA-guided precision neoadjuvant therapy in locally advanced rectal cancer: Insights from the ongoing CINTS-R trial.” European journal of cancer (Oxford, England : 1990) (2026). PMID: 41435753 ↗

    L1bRCTCited in: Landmark Trials and Key Evidence
  231. [231]

    Zhang T, Shi L, Jian L et al.. “Clinical Benefit and Cost-Effectiveness of FOLFOX Versus LCCRT in Neoadjuvant Treatment for Patients with Locally Advanced Rectal Cancer: An Economic Analysis of the FOWARC and PROSPECT Trial.” Annals of surgical oncology (2026). PMID: 41379261 ↗

    L1bRCTCited in: Landmark Trials and Key Evidence
  232. [232]

    Huang Y, Yang X, Qin S et al.. “Effect of Perioperative Glutamine-Enhanced Parenteral Nutrition on Short-Term Outcomes in Colorectal Cancer Patients Undergoing Radical Resection: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.” Technology in cancer research & treatment (2026). PMID: 41891764 ↗

    L1aSR_MA_RCTCited in: Landmark Trials and Key Evidence
  233. [233]

    Abideen ZU, Waseem MH, Shoaib A et al.. “Comparing various bowel preparation regimens in constipated patients undergoing colonoscopy: A systematic review and network meta-analysis of randomised controlled trials.” Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland (2026). PMID: 41684308 ↗

    L1aSR_MA_RCTCited in: Landmark Trials and Key Evidence
  234. [234]

    Garfinkle R, George M, Jethwa K et al.. “Development of a CORe outcome set for clinical trials of RECTal cancer treatment: protocol for the CORRECT initiative.” BMJ open (2026). PMID: 41974548 ↗

    L2bTRIAL_NONRANDOMCited in: Landmark Trials and Key Evidence
  235. [235]

    Chen YD, He ZY, Zhao WJ et al.. “Qu-Shi-Jie-Du Decoction for Prevention of Recurrence and Metastasis in High-Risk Stage II/III Colon Cancer: Study Protocol for a Double-Blind, Randomized, Placebo-Controlled Trial.” Integrative cancer therapies (2026). PMID: 41810508 ↗

    L2bTRIAL_NONRANDOMCited in: Landmark Trials and Key Evidence
  236. [236]

    Shimomura M, Ishikawa S, Miguchi M et al.. “Possible preventive effect of surgical glove compression therapy on oxaliplatin-induced peripheral neuropathy: study protocol of a multicentre, phase II/III, randomised controlled trial-the Hiroshima Surgical Study Group of Clinical Oncology (HiSCO)-12 trial.” BMJ open (2026). PMID: 41698721 ↗

    L2bTRIAL_NONRANDOMCited in: Landmark Trials and Key Evidence
  237. [237]

    Abdulla R, Boxtha C, Courtney EP et al.. “Multilevel Action Toward Colorectal Cancer and Hepatitis C Education and Screening (MATCHES): Study protocol for a hybrid 1 stepped-wedge multibehavioral randomized trial.” Contemporary clinical trials (2026). PMID: 41692274 ↗

    L2bTRIAL_NONRANDOMCited in: Landmark Trials and Key Evidence
  238. [238]

    Guntupalli Y, Nimmagadda R, Potluri V et al.. “Blood-Based Circulating Tumor DNA for Early Detection of Colorectal Cancer: A Systematic Review and Meta-Analysis.” Digestive diseases (Basel, Switzerland) (2026). PMID: 41911100 ↗

    L2aSR_OBSCited in: Prevention and Screening
  239. [239]

    Majsniarova Z, Minarikova D, Minarik P et al.. “Pharmacist-Led Interventions for Colorectal Cancer Prevention: A Systematic Review.” Current oncology (Toronto, Ont.) (2026). PMID: 41892205 ↗

    L2aSR_OBSCited in: Prevention and Screening
  240. [240]

    Ramai D, Pan CW, Rodriguez B et al.. “Interventions for Increasing Colorectal Cancer Screening Uptake: A Systematic Review and Network Meta-Analysis.” Gastroenterology (2026). PMID: 41932450 ↗

    L2aSR_OBSCited in: Prevention and Screening
  241. [241]

    Carbone F, Ciardiello D, Granieri S et al.. “Blood-based circulating tumour DNA (ctDNA) tests for colorectal cancer screening: Systematic review and meta-analysis of diagnostic accuracy.” Critical reviews in oncology/hematology (2026). PMID: 41881272 ↗

    L2aSR_OBSCited in: Prevention and Screening
  242. [242]

    Greene M, Gameng L, Nowd P et al.. “Adherence to Obstetrician-/Gynecologist-Ordered Multi-target Stool DNA Test Screening and Follow-Up Colonoscopy: A National Multi-payer Study of US Women.” Advances in therapy (2026). PMID: 41984312 ↗

    L5OTHERCited in: Prevention and Screening
  243. [243]

    Liao TE, Chuang C, Liu SY et al.. “Klebsiella Pneumoniae Liver Abscess as the Herald of Underlying Colorectal Neoplasm.” Open forum infectious diseases (2026). PMID: 41983149 ↗

    L5OTHERCited in: Prevention and Screening
  244. [244]

    Devall MA, Taha HM, Chen M et al.. “Interrogating the mechanistic link between neighborhood deprivation and colorectal cancer risk through transcriptomic analysis of normal colorectal biopsies.” Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology (2026). PMID: 41979606 ↗

    L5OTHERCited in: Prevention and Screening
  245. [245]

    Vickers AL, Fichera A. “The Evolution of the Management of Dysplasia in Ulcerative Colitis.” Cancers (2026). PMID: 41976387 ↗

    L5REVIEW_NARRATIVECited in: Prevention and Screening
  246. [246]

    Xu S, Gong L, Lu Y et al.. “A simplified multitarget stool test for colorectal cancer and advanced precancerous lesion detection.” Clinical chemistry and laboratory medicine (2026). PMID: 41965119 ↗

    L5OTHERCited in: Prevention and Screening
  247. [247]

    Li X, Zhao Z, Stassen L et al.. “Head-to-head comparison of the diagnostic value of fecal and serum carcinoembryonic antigen for colorectal cancer detection.” International journal of cancer (2026). PMID: 41957956 ↗

    L5OTHERCited in: Prevention and Screening
  248. [248]

    Kim J, Mabiala-Maye G, Michaud T et al.. “Using a cross-sectoral partnership to improve colorectal cancer screening and follow-up among African Americans in the United States: A protocol and preliminary results.” Preventive medicine reports (2026). PMID: 41953108 ↗

    L5OTHERCited in: Prevention and Screening
  249. [249]

    Pi-Chun Chuang M, Hsu WF, Su CW et al.. “Fecal Hemoglobin-Guided Precision Post-polypectomy Surveillance within the Current Framework: A Four-Million-Participant FIT-based Screening Study.” Gastroenterology (2026). PMID: 41932453 ↗

    L5OTHERCited in: Prevention and Screening
  250. [250]

    Lux TJ, Saßmannshausen Z, Kafetzis I et al.. “Artificial intelligence assisted colorectal lesion detection in private practices a randomized controlled study.” NPJ digital medicine (2026). PMID: 41922731 ↗

    L5OTHERCited in: Prevention and Screening
  251. [251]

    de Jong R, De Roover R, Devlin L et al.. “ESTRO technical guideline: intensity modulated radiotherapy and image guided radiotherapy for rectal cancer.” Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology (2026). PMID: 41662929 ↗

    L1cGUIDELINECited in: Guidelines and Resources
  252. [252]

    Kennecke H, Delpassand E, Felder S et al.. “NANETS Guidelines for the diagnosis and management of stage I-III rectal neuroendocrine tumors.” Endocrine-related cancer (2026). PMID: 41562331 ↗

    L1cGUIDELINECited in: Guidelines and Resources
  253. [253]

    Huo B, Arezzo A, Sochorova D et al.. “EAES, ESCP, and ESGAR clinical practice guideline update on taTME for rectal cancer.” Surgical endoscopy (2026). PMID: 41413298 ↗

    L1cGUIDELINECited in: Guidelines and Resources
  254. [254]

    Tanakaya K, Yamaguchi T, Hirata K et al.. “Japanese society for cancer of the colon and rectum (JSCCR) guidelines 2024 for the clinical practice of hereditary colorectal cancer.” International journal of clinical oncology (2026). PMID: 41214301 ↗

    L1cGUIDELINECited in: Guidelines and Resources
  255. [255]

    Korngold EK, Kambadakone AR, Berlin J et al.. “ACR Appropriateness Criteria® Staging and Disease Monitoring of Rectal Cancer.” Journal of the American College of Radiology : JACR (2025). PMID: 41193050 ↗

    L1cGUIDELINECited in: Guidelines and Resources
  256. [256]

    Korngold EK, Kambadakone AR, Berlin J et al.. “ACR Appropriateness Criteria® Staging and Disease Monitoring of Colon Cancer and Appendiceal Cancer.” Journal of the American College of Radiology : JACR (2025). PMID: 41193049 ↗

    L1cGUIDELINECited in: Guidelines and Resources
  257. [257]

    Kinugasa Y, Uehara K, Yamaguchi K et al.. “Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2024 for the treatment of colorectal cancer.” International journal of clinical oncology (2025). PMID: 41186794 ↗

    L1cGUIDELINECited in: Guidelines and Resources
  258. [258]

    Poynten IM, Turner RC, Varma R et al.. “Australian guidelines for anal cancer screening using anal human papillomavirus testing with cytology triage in people living with HIV.” HIV medicine (2025). PMID: 41130598 ↗

    L1cGUIDELINECited in: Guidelines and Resources
  259. [259]

    Ngamruengphong S, Othman MO, Wang AY et al.. “AGA Clinical Practice Update on Endoscopic Resection for Early Colorectal Cancer: Commentary.” Gastroenterology (2025). PMID: 41114683 ↗

    L1cGUIDELINECited in: Guidelines and Resources
  260. [260]

    Gallon R, McCormick L, Saetta A et al.. “EMQN best practice guidelines for analysis and reporting of microsatellite instability in solid tumours.” European journal of human genetics : EJHG (2026). PMID: 40836023 ↗

    L1cGUIDELINECited in: Guidelines and Resources
  261. [261]

    Mussetto A, Radaelli F, Galloro G et al.. “SIED-GISCOR recommendations for colonoscopy in screening programs: Part 2 - Endoscopic treatment.” Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver (2025). PMID: 40784850 ↗

    L1cGUIDELINECited in: Guidelines and Resources
  262. [262]

    Gambella A, Parente P, Grillo F et al.. “Pathology of the malignant colorectal polyp: Issues in morphologic criteria and recommendations from the Italian Group of Gastrointestinal Pathologists.” Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver (2025). PMID: 40769863 ↗

    L1cGUIDELINECited in: Guidelines and Resources
  263. [263]

    Wach MM, Dineen SP. “ASO Practice Guideline Series: Management of Colorectal Peritoneal Metastases.” Annals of surgical oncology (2025). PMID: 40587073 ↗

    L1cGUIDELINECited in: Guidelines and Resources
  264. [264]

    Godfrey EL, Mahoney F, Bansal VV et al.. “Consensus guideline for the management of patients with appendiceal tumors, part 2: Appendiceal tumors with peritoneal involvement.” Cancer (2025). PMID: 40558065 ↗

    L1cGUIDELINECited in: Guidelines and Resources
  265. [265]

    Mali J, Valadão M, Araujo RO et al.. “Brazilian Society of Surgical Oncology: Guidelines for the Lymphadenectomy in Colorectal Cancer.” Journal of surgical oncology (2025). PMID: 40521833 ↗

    L1cGUIDELINECited in: Guidelines and Resources

Revision History

All updates applied to this page

Loading revisions…